0000000000374314

AUTHOR

Elena Turola

showing 4 related works from this author

Neoangiogenesis-related genes are hallmarks of fast-growing hepatocellular carcinomas and worst survival. Results from a prospective study

2016

Objective The biological heterogeneity of hepatocellular carcinoma (HCC) makes prognosis difficult. We translate the results of a genome-wide high-throughput analysis into a tool that accurately predicts at presentation tumour growth and survival of patients with HCC.Design Ultrasound surveillance identified HCC in 78 (training set) and 54 (validation set) consecutive patients with cirrhosis. Patients underwent two CT scans 6 weeks apart (no treatment in-between) to determine tumour volumes (V-0 and V-1) and calculate HCC doubling time. Baseline-paired HCC and surrounding tissue biopsies for microarray study (Agilent Whole Human Genome Oligo Microarrays) were also obtained. Predictors of su…

AdultMale0301 basic medicinemedicine.medical_specialtyTime FactorsCarcinoma HepatocellularTime FactorMicroarrayHepatocellular carcinomamolecular carcinogenesisGastroenterologyliver imagingHEPATOCELLULAR CARCINOMA; LIVER IMAGING; MOLECULAR CARCINOGENESIS; MOLECULAR ONCOLOGY; Adult; Aged; Aged 80 and over; Carcinoma Hepatocellular; Disease Progression; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neovascularization Pathologic; Prospective Studies; Survival Rate; Time Factors; Tumor Burden; Medicine (all); Gastroenterology03 medical and health sciencesmolecular oncology0302 clinical medicineHepatocellular carcinoma liver imaging molecular carcinogenesis molecular oncologyInternal medicinemedicineCarcinomaHumansDoubling timeProspective StudiesProspective cohort studySurvival rateAgedAged 80 and overNeovascularization Pathologicbusiness.industryProportional hazards modelLiver NeoplasmsGastroenterologyMiddle Agedmedicine.diseaseTumor BurdenSurvival RateProspective Studie030104 developmental biologyQuartileLiver Neoplasm030220 oncology & carcinogenesisHepatocellular carcinomaDisease ProgressionFemalebusinessHumanGut
researchProduct

Reproductive status is associated with the severity of fibrosis in women with hepatitis C.

2012

Introduction Chronic hepatitis C is the main cause of death in patients with end-stage liver disease. Prognosis depends on the increase of fibrosis, whose progression is twice as rapid in men as in women. Aim of the study was to evaluate the effects of reproductive stage on fibrosis severity in women and to compare these findings with age-matched men. Materials and Methods A retrospective study of 710 consecutive patients with biopsy-proven chronic hepatitis C was conducted, using data from a clinical database of two tertiary Italian care centers. Four age-matched groups of men served as controls. Data about demographics, biochemistry, liver biopsy and ultrasonography were analyzed. Contrib…

Liver CirrhosisMalemedicine.medical_specialtyGastroenterology and hepatologyLiver CirrhosiPhysiologylcsh:MedicineViral diseasesChronic hepatitis CSeverity of Illness IndexHepatitisLiver diseaseEndocrinologyFibrosisRetrospective StudieSeverity of illnessmedicinegenderHumansReproductive EndocrinologyChronic hepatitis C; genderlcsh:ScienceTestosteroneLiver diseasesRetrospective StudiesGynecologyMultidisciplinarymedicine.diagnostic_testbusiness.industrylcsh:RCase-control studyHepatitis Cmedicine.diseaseHepatitis CMenopauseInfectious hepatitisCirrhosisLiver biopsyCase-Control StudiesMedicineInfectious diseasesWomen's HealthFemalelcsh:QbusinessCase-Control StudieInfertility FemaleResearch ArticleHumanPLoS ONE
researchProduct

Ovarian senescence increases liver fibrosis in humans and zebrafish with steatosis

2015

ABSTRACT Contrasting data exist on the effect of gender and menopause on the susceptibility, development and liver damage progression in non-alcoholic fatty liver disease (NAFLD). Our aim was to assess whether menopause is associated with the severity of liver fibrosis in individuals with NAFLD and to explore the issue of ovarian senescence in experimental liver steatosis in zebrafish. In 244 females and age-matched males with biopsy-proven NAFLD, we assessed anthropometric, biochemical and metabolic features, including menopausal status (self-reported); liver biopsy was scored according to ‘The Pathology Committee of the NASH Clinical Research Network’. Young and old male and female zebraf…

Liver CirrhosisMaleFibrosiBiopsyPhysiologylcsh:MedicineMedicine (miscellaneous)Body Mass IndexCohort StudiesImmunology and Microbiology (miscellaneous)FibrosisNon-alcoholic Fatty Liver DiseaseRisk FactorsOdds RatioZebrafishCellular Senescencemedicine.diagnostic_testAnthropometryFatty liverMiddle AgedOvarian senescenceMenopauseLiver biopsyModels AnimalDisease ProgressionFemaleMenopauselcsh:RB1-214Research ArticleSenescenceAdultmedicine.medical_specialtyFibrosis Menopause Non-alcoholic fatty liver disease Ovarian senescence ZebrafishNeuroscience (miscellaneous)Fibrosis; Menopause; Non-alcoholic fatty liver disease; Ovarian senescence; Zebrafish; Biochemistry Genetics and Molecular Biology (all); Medicine (miscellaneous); Immunology and Microbiology (miscellaneous); Neuroscience (miscellaneous)BiologyReal-Time Polymerase Chain ReactionGeneral Biochemistry Genetics and Molecular BiologyInternal medicinemedicinelcsh:PathologyAnimalsHumansAgedBiochemistry Genetics and Molecular Biology (all)lcsh:RSettore MED/09 - MEDICINA INTERNAOvaryOdds ratiomedicine.diseaseFibrosisEndocrinologySteatosisBody mass indexDisease Models & Mechanisms
researchProduct

Enoxaparin Prevents Portal Vein Thrombosis and Liver Decompensation in Patients With Advanced Cirrhosis

2012

BACKGROUND & AIMS: We performed a randomized controlled trial to evaluate the safety and efficacy of enoxaparin, a low-molecular-weight heparin, in preventing portal vein thrombosis (PVT) in patients with advanced cirrhosis. METHODS: In a nonblinded, single-center study, 70 outpatients with cirrhosis (Child-Pugh classes B7-C10) with demonstrated patent portal veins and without hepatocellular carcinoma were assigned randomly to groups that were given enoxaparin (4000 IU/day, subcutaneously for 48 weeks; n = 34) or no treatment (controls, n = 36). Ultrasonography (every 3 months) and computed tomography (every 6 months) were performed to check the portal vein axis. The primary outcome was pre…

medicine.medical_specialtyCirrhosisIntention-to-treat analysisHepatologybusiness.industrycirrhosisGastroenterologyPortal vein trombosis; Enoxaparin; cirrhosisenoxaparin cirrhosis portal thrombosismedicine.diseasePortal vein trombosisSurgeryPortal vein thrombosislaw.inventionSpontaneous bacterial peritonitisModel for End-Stage Liver DiseaseRandomized controlled triallawHepatocellular carcinomaMedicinePortal hypertensionEnoxaparinbusinessGastroenterology
researchProduct